These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23974194)

  • 1. The impact of response on bone-directed therapy in patients with multiple myeloma.
    Larocca A; Child JA; Cook G; Jackson GH; Russell N; Szubert A; Gregory WM; Brioli A; Owen RG; Drayson MT; Wu P; Palumbo A; Boccadoro M; Davies FE; Morgan GJ
    Blood; 2013 Oct; 122(17):2974-7. PubMed ID: 23974194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
    Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
    Morgan GJ; Davies FE; Gregory WM; Szubert AJ; Bell SE; Drayson MT; Owen RG; Ashcroft AJ; Jackson GH; Child JA;
    Blood; 2012 Jun; 119(23):5374-83. PubMed ID: 22498739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    Morgan GJ; Child JA; Gregory WM; Szubert AJ; Cocks K; Bell SE; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Wu P; Davies FE;
    Lancet Oncol; 2011 Aug; 12(8):743-52. PubMed ID: 21771568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
    Morgan GJ
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S24-30. PubMed ID: 21353177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
    Delea TE; Rotter J; Taylor M; Chandiwana D; Bains M; El Ouagari K; Kaura S; Morgan GJ
    J Med Econ; 2012; 15(3):454-64. PubMed ID: 22316275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.
    Berenson JR
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):2-4. PubMed ID: 22130220
    [No Abstract]   [Full Text] [Related]  

  • 10. Updates in the treatment of multiple myeloma.
    Berenson JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):667-9. PubMed ID: 23187773
    [No Abstract]   [Full Text] [Related]  

  • 11. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
    Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
    J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
    Henk HJ; Teitelbaum A; Perez JR; Kaura S
    Am J Hematol; 2012 May; 87(5):490-5. PubMed ID: 22454220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
    J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Mitsiades CS; Rosenblatt J; Mahindra A; Raje N; Munshi N; Anderson KC
    Eur J Haematol; 2012 Jan; 88(1):1-7. PubMed ID: 21991938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Terpos E; Dimopoulos MA; Berenson J
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
    Søe K; Delaissé JM; Jakobsen EH; Hansen CT; Plesner T
    Acta Oncol; 2014 Apr; 53(4):547-56. PubMed ID: 24164102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid for all patients with newly diagnosed multiple myeloma?
    Terpos E; Dimopoulos MA
    Lancet Oncol; 2011 Aug; 12(8):711-2. PubMed ID: 21771569
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.
    Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Cook G; Drayson MT; Owen RG; Ross FM; Jackson GH; Child JA
    Clin Cancer Res; 2013 Nov; 19(21):6030-8. PubMed ID: 23995858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.